Overview

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

Status:
Not yet recruiting
Trial end date:
2022-05-09
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label Phase IIIb study to evaluate the safety of use of a Prefilled syringe (PFS) containing SOK583A1 (40 mg/mL) and to support the collection of observations of the PFS use for intravitreal injection, when utilized by qualified ophthalmologists, who follow the Instructions for Use (IFU) appropriately to prepare and administer Intravitreal (IVT) injections to patients, suffering from nAMD.
Phase:
Phase 3
Details
Lead Sponsor:
Sandoz
Treatments:
Aflibercept